RCaz/eu-funding-proposals-sft huggingface dataset:
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write a project proposal abstract for 'Master Plan Maintenance' to be submitted under Horizon 2020.

assistant: **Abstract**

Within the Single European Sky technological pillar, the European ATM Master Plan (ATM MP) is the roadmap to the horizon 2035+ to guide and connect ATM Research and Innovation and Deployment in building the future European ATM System.  The European ATM Master Plan Edition 2015 approved by the SESAR Joint Undertaking (SJU) Administrative Board and the European Commission and recently published, sets out Performance Ambitions and a Vision for European ATM, in full alignment with ICAO Global Air Navigation Plan.The ATM MP is composed of three Levels; it can be consulted in the ATM MP Public Portal www.atmmasterplan.eu.By EU Regulation 409/2013, the ATM MP is the essential instrument allowing all European ATM key civil and military stakeholders - Airspace users, Air Navigation Service providers, Airports, Network Manager, Airborne and Ground industry, Standardisation bodies and Professional Staff organisations - to share and further develop this common vision for the future European ATM and setting forth the SESAR solutions which following successful research are likely to be elicited to compose future Common Projects for operationally seamless and cost effective deployment.The ATM MP needs to be a living plan, kept abreast of evolutions of the European ATM performance, progresses of the SESAR solutions research results and of deployment.  The duty of SESAR PJ20 AMPLE (ATM Master PLan for Europe) is to ensure the maintenance, update and alignment of the ATM MP three Levels and its associated Portal as a Common Support Activity of the SESAR 2020 Programme.Under the leadership of EUROCONTROL through facilitated access to information rich performance based civil-military ATM data, PJ20 will bring together contributions of 15 (of 19) SESAR2020 members, ensuring the broad ATM re
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain how 'INTRACELLULAR MECHANISMS of ANTIGEN PROCESSING AND PRESENTATION BY THE MHC CLASS I and CLASS II MOLECULES' goes beyond current state-of-the-art under Fourth Framework.

assistant: **Innovation**

Each team will train a young post-doctoral fellow from an EC member state. major histocompatibility complex (MHC) with peptides derived from protein Importantly, the post docs will integrate into the training programs of the antigens. Therefore, the objective of the project is to unravel the home institutes, and work in selected laboratories of network partners for additional expertise. Additional important measures are annual meetings mechanism leading to peptide loading of MHC class I and class II (2-3 days) attended by all young researchers in the network, and mutual molecules. Part of the project became possible through the recent pioneering discovery by J. Trowsdale and other laboratories that the MHC short-term visits of researchers. encodes a novel set of genes that are crucial for antigen presentation, namely the TAP peptide transporters, proteasome subunits, and HLA-DM. Thus, for MHC class I presentation a major focus will be to understand the specificity and mechanism of the TAP transporters and their associated components. This work will have implications far beyond immunology as the transport mechanism of the large family of ABC transporters (including the multi-drug resistance transporter) is totally unknown. For MHC class II presentation the role of the newly discovered HLA-DM molecule will be a major goal as well as the structure of the MHC class II/Invariant chain (Ii) complex from which Ii has to be removed prior to peptide loading, and, importantly, the intracellular transport of class II molecules and identification of endosomal sub compartments where peptide loading takes place. With these efforts it will be possible to provide a fairly complete picture of the intracellular events important for antigen presentation. The results obtained will be impor
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe how 'A testing bed for the development of high-risk medical devices' will create measurable scientific, societal and economic impact aligned with Horizon 2020.

assistant: **Impact**

TBMED will establish an open innovation testing bed specialized in the development of high-risk devices (≥Class IIb). Due to a long reimbursement processes, patient access to innovative high-risk medical devices in Europe can take four times longer than in the U.S. In addition to this, the new regulations will stricter ex-ante controls for this type of devices. This scenario represents a big challenge for European high-tech SMEs (representing 95% of the MedTech sector in Europe) to maintain their competitiveness and innovation capacity. TBMED will provide an integral service to accelerate the development of medical devices reducing time to market, covering technology development from TRL4-7 based on Quality-by-Design (QbD) concept and business management services. QbD concept enhances product and process understanding together with process control, based on robust scientific knowledge and quality risk management. Once operating (M37) the OITB will integrate: 1) an SME office that will provide business advice and IP management, 2) services on regulation, early health technology assessment advice and QbD, 3) a biomaterial synthesis lab, 4) characterization facilities, 5) a testing lab for in vivo and in vitro efficacy testing, 6) safety assessment and 7) clinical testing. Three case studies will be used to validate the concept and will help to establish the OITB: 1) An osteoinductive hydrogel, 2) Keratoprosthesis and 3) Magnetic NPs for hyperthermia. TBMED consists of 13 complementary partners composed by 1 Industry and 2 SMEs developers of 4 different medical devices used as case studies, 5 RTD institutions experts in the development of medical devices, 1 SME expert in QbD methodology, 2 RTD Institutions that will provide the access to a hospital network with experience
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'State of the Art and Innovation' section for a Horizon Europe proposal on 'Developing the next generation of cis-targeting macrophage-T cell cancer immunotherapies'.

assistant: **Innovation**

Immunotherapy holds great promise for the curative treatment of millions of cancer patients, with a market size of over 100 billion USD today, which is expected to at least double in the next decade. Cancer immunotherapies are designed either to promote anti-tumor immune activity in the tumor microenvironment (TME), via molecules such as cytokines and antibodies, or to inhibit negative T cell signals induced by cancer and antigen-presenting cells (APCs) in the TME, an approach known as immune checkpoint blockade (ICB). Yet current immunotherapies have shown significant clinical success only against a limited number of cancers, for two major reasons: insufficient anti-tumor immune activation or severe side effects and toxicity as a result of nonspecific immune activation. We propose to overcome these two challenges through the development of a novel class of molecules capable of simultaneously modulating the myeloid and lymphoid immune cell compartments in the TME and generating a highly specific and extremely potent antitumor immune response. In this PoC grant, we seek to validate the ability to construct such dual-modulatory agents, which will provide us with the proof-of-concept for these technologies.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft the 'Objectives and Scope' section of a Seventh Framework proposal for the project 'A combined evolutionary and proteomics approach to the discovery, induction and application of antiviral immunity factors'.

assistant: **Objectives**

Humans are equipped with a variety of intrinsic immunity or host restriction factors. These evolved under positive selection pressure for diversification and represent a first line of defence against invading viruses. Unfortunately, however, many pathogens have evolved effective antagonists against our defences. For example, the capability of HIV-1 to counteract human restriction factors that interfere with reverse transcription, uncoating and virion release has been a prerequisite for the global spread of AIDS. We are just beginning to understand the diversity and induction of antiretroviral factors and how pandemic HIV-1 group M (major) strains evolved to counteract all of them. Here, I propose to use a genetics, proteomics and evolutionary approach to discover and define as-yet-unknown antiviral effectors and their inducers. To identify novel antiviral factors, we will examine the capability of all primate genes that are under strong positive selection pressure to inhibit HIV and its simian (SIV) precursors. This examination from the evolutionary perspective of the invading pathogen will also reveal which adaptations allowed HIV-1 to cause the AIDS pandemic. Furthermore, complex peptide-protein libraries representing essentially the entire human peptidome, will be utilized to identify novel specific inducers of antiviral restriction factors. My ultimate aim is to unravel the network of inducers and effectors of antiviral immunity - the ""Anti-Virome"" - and to use this knowledge to develop novel effective preventive and therapeutic approaches based on the induction of combinations of antiviral factors targeting different steps of the viral life cycle. The results of this innovative and interdisciplinary program will provide fundamental new insights into intrinsic imm
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose a compelling abstract for 'Transcriptional networks controlling lymphocyte development' demonstrating excellence, impact and implementation quality for a Seventh Framework call.

assistant: **Abstract**

Acquired immunity to foreign pathogens depends on functional B and T cells. The objective of this proposal is to elucidate the transcriptional control of lymphocyte development at three stages by deciphering the transcriptional networks specifying pro-B and pro-T cells in early lymphopoiesis and plasma cells in terminal B cell differentiation.To this end, we generated knock-in mice carrying a biotin acceptor sequence at the C-terminus of transcription factors, which can be biotinylated by transgenic co-expression of the E. coli biotin ligase BirA. In vivo biotinylation facilitates antibody-independent precipitation of these transcription factors by streptavidin pulldown (Bio-ChIP). Preliminary Bio-ChIP sequencing experiments validated this approach for genome-wide identification of transcription factor target genes.Bio-ChIP sequencing will be used to identify the target genes of key transcription factors controlling the development of pro-B cells (Ikaros, E2A, STAT5, EBF1, Pax5, PU.1, IRF4), pro-T cells (Notch1, RBP-J, GATA3, Ikaros, E2A, STAT5) and plasma cells (Blimp1, IRF4, XBP1). RNA sequencing of wild-type and mutant lymphocytes will determine the regulated target genes of these factors, which are ultimately relevant for the elucidation of transcriptional networks. The function of selected target genes at central nodes of these networks will be analyzed by the latest miR30-shRNA knockdown technology. Finally, regulatory complexes interacting with these transcription factors will be identified by streptavidin-pulldown purification and mass spectrometry followed by their integration into the transcriptional networks by ChIP-seq mapping to the transcription factor target genes.These experiments will provide fundamentally new molecular insight into the generation of a
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write a project proposal abstract for 'MANpower - Energy Harvesting and Storage for Low Frequency Vibrations' to be submitted under Seventh Framework.

assistant: **Abstract**

Energy harvesting at low frequency has proven to be difficult to achieve in the past because of the properties of the materials that the devices are fabricated from. In particular the stiffness of conventional silicon and all piezoelectric materials makes it exceedingly difficult to make a system that can operate below 100Hz. There are many sources of low frequency vibrations e.g. human motion, the motion of ships, and traffic; so an Energy Harvester that can operate in this frequency range would have a large commercial potential and extensive opportunities for future exploitation. This multi disciplinary project proposal addresses the lack of durable energy harvesting systems in this frequency range. With primary objectives of the project being the development of materials and devices for;• Low frequency tunable energy harvesting device and• High energy density compact supercapacitors for energy storage with secondary objectives being:- The necessary electronics to connect them and make them work efficiently- Packaging technologies that will integrate the full system and make it biocompatible- A study of component reliability and models that can project their lifetime- An end of life study and an environmental impact assessmentPerpetually self powered electronic systems that can be implanted into the human body is the application area that we have targeted for demonstration of this technology, because there are a  clear set of requirements which will motivate the design, fabrication and test of the system under consideration. The two primary objectives present a range of novel and substantial materials challenges in both making the components, achieving a reliable unattended operational extended lifetime and ensuring that the devices are not toxic to the host that they
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose a compelling abstract for 'Bound to accelerate the roll-out and expansion of Energy Communities and empower consumers as fully-fledged energy market players' demonstrating excellence, impact and implementation quality for a Horizon Europe call.

assistant: **Abstract**

With its “Clean Energy for all Europeans” package (CEP), the European Commission formally recognised and instrumentally brought forward community energy projects, including definitions for “Renewable Energy Communities” (RECs) and for “Citizen Energy Communities” (CECs). The new concepts introduced in the CEP set the course for a more active role of EU citizens in the energy markets. To fully concretize the benefits envisioned by the CEP, a myriad of barriers needs to be overcome and progress needs to be done to clarify and streamline the concepts of REC and CEC, enabling its uptake by all interested citizens.Motivated by that challenge, COMMUNITAS will promote energy citizenship, enabling citizens to take control of their own path towards sustainability by becoming an active element of the energy markets. The project will deliver a Knowledge Base that will provide users with technical, administrative, and legal information on ECs, streamlining the creation and expansion of this concept. COMMUNITAS will also deliver an innovative set of tools - capitalizing on technologies such as IoT, Blockchain and Cloud Computing - to unlock citizens’ active participation in energy markets and communities (all integrated into an open, digital “one-stop-shop” COMMUNITAS Core Platform (CCP)), allowing EC members to have an aggregated position in the energy markets or explore ancillary services using different energy assets or load profiles of the community.As a project that aims to position citizens in the centre of energy markets, COMMUNITAS has citizens at the centre of its own approach: citizens will be involved in Social and Policy Labs throughout the whole project, in order to frequently factor in their feedback, wishes, needs into the core developments of the project.


**Keyword
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an impact statement for 'Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes', explaining its relevance to EU policy priorities under Seventh Framework.

assistant: **Impact**

Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biological subtypes of these cancers. Here, we will explore the rate of activation of all kinases (the “kinome”) in two poor-prognosis subtypes of breast cancer for which there are currently no targeted therapies available, namely “triple negative” (TN) breast tumors lacking the estrogen-, progesterone- and HER2 receptors, constituting 15% of breast cancers, and invasive lobular carcinomas (ILC) of the breast, which represent 10% of breast tumors. Thus, we lack effective targeted therapies for one quarter of all breast cancer patients. In this project, we will identify and validate novel kinase targets for therapy for these TN and ILC subtypes. Kinase targets will be identified via a 5-pronged approach: i) direct re-sequencing of the kinome of 150 TN and 150 ILC tumors, ii) determination of abundance and activation status of kinases in these tumors by reverse phase protein array and tissue microarray technologies, iii) determination of copy number variation by SNP arrays, and iv) mRNA quantitation of the kinome using DNA microarrays and v) RNA sequencing to provide complementary information such as evidence of alternative splicing, translocations and RNA editing within the expressed kinome. Potential kinase targets for therapy will be validated in preclinical models using RNA interference. Finally, we will perform a phase I/II clinical trial to test the efficacy of a selective PI3K inhi
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose the 'State of the Art and Innovation' section for a Seventh Framework proposal on 'Inflammatory Bowel Disease: an EU-NZ integrated approach for characterizing its molecular multifactorial mechanisms'.

assistant: **Innovation**

Over the past 20 years there has been a dramatic rise in the incidence of Inflammatory bowel disease (IBD), both in EU and NZ. IBD refers primarily to two major disorders such as ulcerative colitis (UC) and Crohn's disease (CD), chronic conditions characterized by inflammatory lesions involving gut mucosa. CD is also an emerging problem amongst children. Etiology of IBD is still unknown, however several studies demonstrate multifactorial mechanisms contributing to its pathogenesis (i.e. immunoregulatory defects, genetic mutations, dysbiosis of commensal enteric microbiota, alterations in mucosal permeability, alimentary factors). The complexity of these factors makes necessary for a researcher to acquire the widest spectrum of advanced techniques enabling the deeper understanding of IBD onset and recurrence and developing useful therapeutic strategies. Both Eu and NZ have significantly contribute to IBD research advances, by developing outstanding research expertise and being equipped with the most advance methodological tools. REINFORCE consortium is a multidisciplinary scientific network, in which each partner is a leader in IBD mechanisms. The high level of synergies within REINFORCE consortium, highlighting the cross-talk among different disciplines, will provide a multidisciplinary training for EU and NZ researchers. This joint exchange programme represents a unique opportunity to lead to a high degree of novelty in IBD training by allowing to build up a new profile of researcher able to tackle the different aspects of IBD. REINFORCE has settled down a series of specific and technical objectives which will guarantee the ESRs and ERs to be provided with training tools ensuring the use of the most advanced molecular and cellular techniques. Training modules will conc